AbbVie Sold AndroGel Without Heart Risk Warning, Jury Told

Law360, Chicago (July 5, 2017, 8:43 PM EDT) -- AbbVie Inc. knew its product AndroGel wasn't approved to treat age-related drops in testosterone, but the company marketed it for that while downplaying an associated risk of heart attacks, attorneys for a man who nearly died after using it told an Illinois federal jury on Wednesday.

During opening statements on the first day of trial in Jesse Mitchell's lawsuit against AbbVie, Mitchell's attorney said AbbVie ignored repeated warnings from the U.S. Food and Drug Administration that AndroGel was not approved to treat anything other than a specific group of diseases under the hypogonadism umbrella.

Instead, they embarked on a marketing campaign...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!